Slate Run Pharmaceuticals recalls
Slate Run Pharmaceuticals is named on 2 recalls in Recall Relay's records since November 2023, from FDA (3 recalled products: FDA lists each product as its own recall); the most recent was February 12, 2026.
All 3 recalled products, newest first.
-
Class IIIofficial
Slate Run Pharmaceuticals recalls Eptifibatide InjectionLabeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
-
Class IIofficial
Slate Run Pharmaceuticals recalls Cinacalcet Hydrochloride Tablets 30 mgCGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
-
Class IIofficial
Slate Run Pharmaceuticals recalls Cinacalcet Hydrochloride Tablets 60 mgCGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
This page groups recalls by the company name the agency printed, so it can include different companies with similar names, and a recall may name a store or distributor rather than the maker. It counts the recalls in Recall Relay's records, not a company's whole history; an FDA recall that lists several products counts once. Open a recall to see its details and the agency's official notice, which is always the final word. Recall Relay isn't affiliated with any agency or with the companies named here.
Severity labels say where they come from: “official” is the agency's own class, “advisory” is based on the agency's safety warning, and “est. risk” is Recall Relay's estimate from the hazard description, not an agency classification.
Hear about the next one
Recall Relay can email you when a new recall mentions Slate Run Pharmaceuticals or any words you choose. Start with a free key (no card needed), then set up alerts on your account page.
Get recall alerts